http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2422263-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4eb6dbca25e5f9459a6c5f592728c787 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D513-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-542 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-429 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D513-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2009-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1db082415349a5a9dc7d3d277d0f716 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3727507ab20c899d1a60359c12e2a8b5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6231253f5ac2bbd3c66a7b1449790385 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c4ce4928d2fc607a7dfd48a4a743592 |
| publicationDate | 2013-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2422263-T3 |
| titleOfInvention | Bicyclic pyrazoles as protein kinase inhibitors |
| abstract | A compound of formula (I): ** Formula ** where: X is CH or N; R1 is hydrogen, halogen, NR7R8, NHCOR9, SR10 or SO2R, where: R7 and R8 are, independently of each other, hydrogen, or an optionally substituted group selected from (C1-C8) alkyl, linear or branched alkyl, cycloalkyl (C3- C8), heterocyclyl, aryl, and heteroaryl, or R7 and R8 taken together can form a groupoftallyl, R9 is OR10, NR11R12, or an optionally substituted group selected from (C1-C8) alkyl, straight or branched alkyl, (C2-C8) alkenyl, or (C2-C8) alkenyl, (C3-C8) cycloalkyl, heterocyclyl, aryl and heteroaryl, R10 is an optionally substituted group selected from linear or branched (C1-C8) alkyl, (C3-C8) cycloalkyl, heterocyclyl, aryl and heteroaryl, R11 and R12 are, independently of one another, hydrogen or an optionally substituted group selected from linear or branched (C1-C8) alkyl, (C3-C8) cycloalkyl, heterocyclyl, aryl and heteroaryl, or taken together with the nitrogen atom to which are joined R11 and R12 can form an h optionally substituted 3-8 membered heterocyclyl or heteroaryl, optionally containing an additional heteroatom or heteroatomic group selected from S, O, N or NH. |
| priorityDate | 2008-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457444288 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID783 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425193155 |
Total number of triples: 31.